Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
- 13 January 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Neurobiology
- Vol. 59 (3), 1850-1861
- https://doi.org/10.1007/s12035-021-02696-0
Abstract
SARS-CoV-2 infects cells via its spike protein binding to its surface receptor on target cells and results in acute symptoms involving especially the lungs known as COVID-19. However, increasing evidence indicates that many patients develop a chronic condition characterized by fatigue and neuropsychiatric symptoms, termed long-COVID. Most of the vaccines produced so far for COVID-19 direct mammalian cells via either mRNA or an adenovirus vector to express the spike protein, or administer recombinant spike protein, which is recognized by the immune system leading to the production of neutralizing antibodies. Recent publications provide new findings that may help decipher the pathogenesis of long-COVID. One paper reported perivascular inflammation in brains of deceased patients with COVID-19, while others showed that the spike protein could damage the endothelium in an animal model, that it could disrupt an in vitro model of the blood-brain barrier (BBB), and that it can cross the BBB resulting in perivascular inflammation. Moreover, the spike protein appears to share antigenic epitopes with human molecular chaperons resulting in autoimmunity and can activate toll-like receptors (TLRs), leading to release of inflammatory cytokines. Moreover, some antibodies produced against the spike protein may not be neutralizing, but may change its conformation rendering it more likely to bind to its receptor. As a result, one wonders whether the spike protein entering the brain or being expressed by brain cells could activate microglia, alone or together with inflammatory cytokines, since protective antibodies could not cross the BBB, leading to neuro-inflammation and contributing to long-COVID. Hence, there is urgent need to better understand the neurotoxic effects of the spike protein and to consider possible interventions to mitigate spike protein-related detrimental effects to the brain, possibly via use of small natural molecules, especially the flavonoids luteolin and quercetin.Keywords
This publication has 236 references indexed in Scilit:
- Evidence for Cognitive Impairment in Mastocytosis: Prevalence, Features and Correlations to DepressionPLOS ONE, 2012
- Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathwaysCardiovascular Diabetology, 2012
- Flavonoid‐mediated presenilin‐1 phosphorylation reduces Alzheimer's disease β‐amyloid productionJournal of Cellular and Molecular Medicine, 2009
- Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expressionJournal of Neuroinflammation, 2008
- Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Corticotropin-releasing hormone and the blood-brain-barrierFrontiers in Bioscience-Landmark, 2007
- Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in PathogenesisClinical Infectious Diseases, 2005
- IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosisClinical Immunology, 2005
- Mast cells: The immune gate to the brainLife Sciences, 1990
- Influence of monoamine oxidase inhibitors and a dopamine uptake blocker on the distribution of11C-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,11C-MPTP, in the head of the Rhesus monkeyActa Neurologica Scandinavica, 1986